IDEAYA Biosciences, Inc. (Nasdaq:IDYA), a precision medicine oncology company committed to the discovery and development of targeted therapeutics, announced the initiation of a Phase 1/2 expansion in ...

Bayer BAYRY announced a licensing agreement with Suzhou Puhe BioPharma Co., a clinical-stage biotechnology company.Suzhou ...

The German conglomerate announced a licensing agreement with Puhe BioPharma for a PRMT5 inhibitor used in a variety of ...

Bayer, Puhe BioPharma ink global license pact to develop, manufacture and commercialize the MTA-cooperative PRMT5 inhibitor: Berlin, Germany Saturday, March 29, 2025, 12:00 Hrs [I ...

A Phase I first-in-human dose escalation study to test it under the name BAY 3713372 in MTAP-deleted solid tumors has already begun with the enrollment of the first patient. “We are looking ...

MTAP Technologies is a company based in Bengaluru, Karnataka, India, operating in the enterprise tech sector. Founded in 2013 and the company was established by Satvir Singh Kohli, Shiv Kumar ...

Bayer and Suzhou Puhe BioPharma Co. Ltd., a clinical-stage biotechnology company, on Wednesday announced that they have entered into a global license agreement for Puhe BioPharma's oral, small ...

IDEAYA Biosciences, Inc. (Nasdaq:IDYA), a precision medicine oncology company committed to the discovery and development of ...

The metabolic enzyme 5’-deoxy-5'-methylthioadenosine phosphorylase (MTAP) is involved in the methionine salvage pathway, which recycles methionine from methylthioadenosine (MTA). Bayer believes ...